On this page
Back to topSpyGlass Pharma SGP
SpyGlass Pharma listed on Nasdaq on 6 Feb 2026 and is not in the S&P 500. It is worth $1.0 billion. Its price history starts on 6 Feb 2026. Its board has 10 directors, 8 of them independent. 3 other officers are on file. At 30 Jun 2026, Ra Capital Management was its largest institutional holder, with 24.0% of the company.
- CEO
- Patrick H. Mooney
- Chair
- Malik Y. Kahook
- Listed
- 6 Feb 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Irvine, CA
- Market cap
- $1.0B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
SpyGlass Pharma's market cap since February 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $1.1B |
Download SpyGlass Pharma's data as JSON, with the weekly market caps in billions of dollars from 6 Feb 2026.
Board and leadership
Board and officers
Board from the proxy filed 26 Mar 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (10) | |||||
| Malik Y. KahookChairNot independent 路 since 2019 | |||||
| Patrick H. MooneyChief Executive OfficerNot independent 路 since 2021 | |||||
| Ali BehbahaniDirectorIndependent 路 CompensationAffiliate, New Enterprise Associates | |||||
| Habib J. DableDirectorIndependent 路 since 2026 路 CompensationDirector | |||||
| Michael Dybbs, Ph.D.DirectorIndependent 路 since 2025 路 AuditAffiliate, Samsara BioCapital | |||||
| Bilal Arshad KhanDirectorIndependent 路 since 2023 路 Compensation (chair), Nominating and Corporate GovernanceChief Executive Officer, New World Medical, Inc. | |||||
| Kirk G. NielsenDirectorIndependent 路 since 2025 路 AuditManaging Director, Vensana Capital | |||||
| Elizabeth G. O'FarrellDirectorIndependent 路 since 2025 路 Audit (chair)Director | |||||
| Geoff PardoDirectorIndependent 路 since 2025 路 Nominating and Corporate GovernancePresident and General Partner, Gilde Healthcare US Inc.Other boards: Mainstay Medical Holding | |||||
| Zach Scheiner, Ph.D.DirectorIndependent 路 since 2023 路 Nominating and Corporate Governance (chair)Partner, RA Capital Management, L.P.Other boards: Nkarta Therapeutics and LENZ Therapeutics | |||||
| Officers (3) | |||||
| Jean-Frederic ViretChief Financial OfficerLast filed 9 Feb 2026 | |||||
| James Robert Dennewill Jr.Chief Operating OfficerLast filed 9 Feb 2026 | |||||
| Chetan Pratap PujaraChief R&D OfficerLast filed 9 Feb 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of SpyGlass Pharma. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $83.9 million in 6 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 16 Nov 2026Buy | Peter KolchinskyDirector | $32K |
| 9 Feb 2026Buy | Peter KolchinskyDirector | $59M |
| 9 Feb 2026Buy | Ali BehbahaniDirector | $15M |
| 9 Feb 2026Buy | Geoffrey B. PardoDirector | $5.0M |
| 9 Feb 2026Buy | Kirk G. NielsenDirector | $2.6M |
| 9 Feb 2026Buy | Bilal Arshad KhanDirector | $2.2M |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
0 departures and 1 appointment of directors and officers in the last two years.
Events, newest first
- 5 Feb 2026 Habib Dable appointedDirector
| Date | Event | Filing |
|---|---|---|
| 5 Feb 2026 | Habib Dable appointedDirector | 8-K |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.